Freedom of Information Request 0338 2019/20
This is a freedom of information request relating to patients being treated for multiple myeloma or chronic lymphocytic leukaemia.
- Does your trust treat adult multiple myeloma [MM] ? – if you refer your multiple myeloma patients to another centre, please state which.
- If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;
- Bortezomib [Velcade]
- Carfilzomib [Kyprolis]
- Ixazomib [Ninlaro]
- Lenalidomide [Revlimid]
- Daratumumab [Darzalex]
- Melphalan, prednisolone and thalidomide (known as MPT)
- Cyclophosphamide, thalidomide and dexamethasone (known as CTD)
- Pomalidomide [Imnovid]
- Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
If possible, how many CLL patients treated were new to therapy in the past 3 months?
- How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
- Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)
- Bendamustine and rituximab (known as BR)
- Ibrutinib [Imbruvica]
- Chlorambucil
- Venetoclax
- Obinutuzumab
- Idelalisib
- Fludarabine and rituximab (known as FR)
- High-dose prednisone and rituximab
- Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)
- Alemtuzumab (Campath) with rituximab
